The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald ...
Experts say two new guidances — issued without the usual public comment period — leave questions about how patients will ...
The agency is currently reviewing the study findings ...
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
At the highest levels of the FDA, questions remain about which officials have the legal authority to sign off on drugs cleared under the Commissioner’s National Priority Voucher program, which ...